-

Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Longboard (NASDAQ: LBPH) for possible breaches of fiduciary duty and other violations of law in its transaction with Lundbeck.

Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Longboard shareholders will receive only $60.00 per share in a tender offer that values the Longboard at approximately $2.6 billion equity value. The transaction agreement unreasonably limits competing transactions for Longboard by imposing a significant penalty if Longboard accepts a competing bid. Longboard insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Longboard’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Longboard common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or here.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Ademi LLP

NASDAQ:LBPH

Release Versions

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

More News From Ademi LLP

Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable CVR to receive certain milestone payme...

Shareholder Alert: The Ademi Firm Investigates Whether Paramount Group Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Paramount (NYSE: PGRE) for possible breaches of fiduciary duty and other violations of law in its transaction with a Rithm Capital. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Paramount will receive $6.60 per fully diluted share in an all-cash transaction valued at approximately...

Shareholder Alert: The Ademi Firm Continues to Investigate Whether TEGNA Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating TEGNA (NYSE: TEGNA) for possible breaches of fiduciary duty and other violations of law in its going-private transaction. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of TEGNA will receive $22.00 per share in an all-cash transaction valued at $6.2 billion, including TEGNA's net debt...
Back to Newsroom